How Many Calories Per Day on a GLP-1 Drug
Fitness methodology by Andrew Menechian, Head of Fitness, FitCommit|Last updated: 2026-05-15
Quick Answer
There is no single calorie target for every GLP-1 user. A safer approach is to estimate current TDEE, choose a moderate deficit when fat loss is the goal, and treat protein plus basic nutrition as floors. If appetite suppression makes it difficult to eat enough, that is a medication-tolerance issue to discuss with the prescribing clinician, not a signal to push harder.
Medication Boundary
- This page is nutrition support, not medical advice.
- Do not change your medication dose, timing, or schedule from this page.
- Talk with the prescribing clinician if nausea, dizziness, dehydration, constipation, very low intake, or medication questions show up.
- If you experience sudden vision loss or rapidly worsening eyesight while taking semaglutide, contact the prescribing clinician without delay.
- Ozempic and Wegovy have different approved uses and dosing contexts even though both contain semaglutide.
- FitCommit helps with food logging, protein planning, and body-composition tracking. It does not prescribe, monitor, or manage GLP-1 medication.
Key Questions
How many calories should I eat on Ozempic?
Start from your current TDEE, not a universal number. Many people use a moderate deficit during fat loss, but the right intake depends on body size, activity, medical status, symptoms, and clinician guidance.
Can calories get too low on a GLP-1?
Yes. If appetite suppression makes normal eating difficult, protein, micronutrients, training performance, and energy can suffer. Persistent inability to eat enough should be discussed with the prescribing clinician.
Should I track calories or macros?
Track both if possible. If appetite is very low, prioritize protein and basic nutrition floors first, then use calories to avoid drifting into an overly aggressive deficit.
Overview
GLP-1 drugs reduce appetite. That can make a calorie deficit feel easier, but it can also hide under-eating. FitCommit should avoid universal calorie prescriptions because the safe range depends on body size, activity, health history, dose tolerance, and the clinician managing the medication. The practical goal is to turn appetite suppression into a controlled nutrition plan instead of letting hunger disappear as the only guardrail.
When Eat Less Becomes Eat Enough
Use calories as a range
A narrow target can backfire when appetite is low. Use a practical range and keep protein, fluids, and fiber visible.
Flag under-eating early
Dizziness, unusual fatigue, fast strength loss, or inability to finish small meals means the plan needs review.
Separate nutrition from dose decisions
FitCommit can show the intake pattern. The prescribing clinician owns dose tolerance, side effects, and medication changes.
Protein target check
Estimate your GLP-1 protein range
Use this as a planning range, not a prescription. FitCommit uses 1.2 to 1.6 g per kg per day here because low appetite can make protein gaps easy to miss.
For full macros by goal and training status, use the FitCommit protein calculator.
The Protocol
- 1
Estimate current TDEE
Use current body weight and activity level. Recalculate after meaningful weight change because maintenance calories decline as body weight declines.
Why: A target that made sense 20 lb ago may be too high or too low now.
- 2
Set protein as a floor
Use a practical protein range and confirm it in grams. The 1.2 to 1.6 g/kg body-weight range is a conservative floor; lean-body-mass-based targets can be higher when preserving lean mass during a deficit matters.
Why: Protein can fall short when appetite drops, and that is one of the most controllable body-composition risks.
- 3
Use calories to prevent both over- and under-shooting
Treat calories as a range, not a dare. If intake is consistently very low, add tolerated foods or talk with your clinician about side-effect management.
Why: The drug may create the deficit. Your job is to keep the deficit nutritionally usable.
- 4
Watch performance and symptoms
Track energy, training performance, nausea, constipation, dizziness, and ability to complete normal meals.
Why: Symptoms often reveal that the calorie target is less important than medication tolerance and nutrition adequacy.
Warning Signs
- !You regularly cannot finish small protein-focused meals.
- !You feel dizzy, weak, or unusually fatigued while intake is low.
- !Training performance is dropping quickly.
- !You are using a fixed calorie floor without considering body size, symptoms, or clinician guidance.
- !You are changing medication dose to manage calories without discussing it with the prescribing clinician.
GLP-1 lowers hunger. Protein still needs a plan.
Log meals quickly and see your protein gap in real time.
Try FitCommit FreeFrequently Asked Questions
Is 1,200 calories always the minimum?
Do calories still matter on a GLP-1 drug?
What should I do if I am barely eating?
How often should I recalculate calories?
Evidence
Semaglutide 2.4 mg produced substantial mean weight loss in STEP 1.
Strong- What the source supports
- Supports the premise that GLP-1 treatment can meaningfully reduce energy intake and body weight in studied populations.
- What it does not prove
- Does not provide an individual calorie target and does not remove the need to monitor nutrition adequacy.
Wegovy delays gastric emptying and may affect absorption of oral medications.
Strong- What the source supports
- Supports the warning that low appetite and gastric-emptying effects can change how eating feels during treatment.
- What it does not prove
- Does not provide a universal calorie floor and does not support self-directed medication changes.
- Source
- FDA Wegovy label
The STEP 1 DEXA substudy reported total lean body mass decline alongside larger fat-mass decline.
Moderate to strong- What the source supports
- Supports tracking protein and basic nutrition quality while weight is dropping.
- What it does not prove
- Does not prove a specific calorie minimum and does not show that all lean-mass change is muscle tissue.
Higher protein intake was associated with lower muscle-loss risk in a small semaglutide study, but the authors called for more research.
Moderate- What the source supports
- Supports a cautious protein-planning signal from an early semaglutide study reported by the Endocrine Society.
- What it does not prove
- Does not prove a universal protein dose, does not replace medical nutrition therapy, and should not be treated as definitive GLP-1 muscle-preservation evidence.
Protein supplementation supports resistance-training gains in healthy adults, with effect estimates plateauing near 1.6 g/kg/day in the meta-regression.
Strong- What the source supports
- Supports the general protein and resistance-training range used as a planning anchor for active adults, while FitCommit uses lean-body-mass-based targets for more specific body-composition planning.
- What it does not prove
- Does not study GLP-1 medication users directly and does not establish a medication-specific protein prescription.
EMA PRAC concluded NAION is a very rare side effect of semaglutide medicines and advised prompt medical contact for sudden vision loss or rapidly worsening eyesight.
Moderate to strong- What the source supports
- Supports a visible medication-safety boundary for urgent vision symptoms and reinforces that semaglutide pages should not minimize eye-related adverse-event concerns.
- What it does not prove
- This does not prove that every vision event was caused by semaglutide, does not quantify individual risk, and does not support stopping or changing medication without the prescribing clinician.